GlassScriptPhysician profile
Heather L Benjamin
NPI 1619046604
$106,020.74
in general payments reported to CMS, 2019-2025
22 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $27K · 2021: $12K · 2022: $4,445 · 2023: $1,546 · 2024: $144 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,258 · Food and Beverage: $553 · Consulting Fee: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,258.29 |
| Food and Beverage | $552.90 |
| Consulting Fee | $275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34,987.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $31,293.69 | 2019-2025 | Imfinzi |
| Exelixis INC. | $6,264.58 | 2019 | |
| Eli Lilly and Company | $5,688.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $4,940.81 | 2019-2022 | |
| R-Pharm US LLC | $4,295.28 | 2019 | |
| Abbvie INC. | $4,097.27 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $3,777.86 | 2019 | |
| Mylan Institutional INC. | $3,759.20 | 2019 | |
| Hologic Sales and Service, LLC | $1,546.27 | 2023 | Btx, Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Pharmacosmos Therapeutics INC. | $1,500.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,100.00 | 2019 | |
| Becton, Dickinson and Company | $600.00 | 2020 | |
| Daiichi Sankyo INC. | $550.00 | 2022 | |
| Glaxosmithkline, LLC. | $425.00 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $300.00 | 2020 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Merck Sharp & Dohme LLC | $122.31 | 2019 | |
| Gilead Sciences, INC. | $110.16 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.